Patients with type 2 diabetes mellitus present similar immunological response to COVID-19 BNT162b2 mRNA vaccine to healthy subjects: a prospective cohort study

Hormones (Athens). 2023 Mar;22(1):5-11. doi: 10.1007/s42000-022-00405-7. Epub 2022 Oct 21.


Aim: To compare the kinetics of neutralizing antibodies (NΑbs) against SARS-CoV-2 after vaccination with the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech) between patients with T2DM and healthy controls.

Methods: NAb levels after the BNT162b2 mRNA vaccine were compared between 50 patients with non-insulin treated T2DM and 50 age-, gender-, and BMI-matched healthy controls up to 3 months after the second dose. The median age of both groups was 70 years.

Results: On day 1, mean NAbs of the control and T2DM groups were 14.64% (standard error, SE = 2.30) and 14.04% (SE = 2.14), respectively (p value = 0.926). Three weeks later, the mean NAb values were 39.98% (SE = 3.53) in the control group and 40.97% (SE = 3.99) in participants with T2DM (p value = 0.698). One month after the second vaccination, mean NAb values increased to 87.13% (SE = 2.94) in the control group and 89.00% (SE = 2.18) in the T2DM group. Three months after the second vaccine dose, the mean inhibitory titers decreased to 83.49% (SE = 3.82) (control group) and 76.36% (SE = 3.33) (T2DM group). On all occasions, no significant difference was found between the two groups (all p values > 0.05).

Conclusions: Patients with T2DM present similar immunological response to COVID-19 BNT162b2 mRNA vaccine to that of healthy subjects.

Keywords: COVID-19; Diabetes mellitus; Hyperglycemia; Immune response; SARS-CoV-2; Type 2 diabetes; Vaccination.

MeSH terms

  • Aged
  • BNT162 Vaccine
  • COVID-19* / prevention & control
  • Diabetes Mellitus, Type 2*
  • Healthy Volunteers
  • Humans
  • Infant
  • Prospective Studies
  • SARS-CoV-2
  • mRNA Vaccines


  • BNT162 Vaccine